medigraphic.com

2023, Number 3

<< Back Next >>

Rev Mex Anest 2023; 46 (3)

Malignant hyperthermia in a patient undergoing Madden type radical mastectomy

Vázquez-Morales H, Jaime-Córdova A, Vargas-Sánchez V

Language: Spanish
References: 15
Page: 208-211
PDF size: 256.02 Kb.


ABSTRACT

The objective of the present is to present the anesthetic management that occurred before a critical event malignant hyperthermia HM) in an electively scheduled Madden radical mastectomy and which was managed with what was available at that time for not having the drug specific (dantrolene) for this type of event HM. Breast cancer is a complex disease, being the leading cause of death in women worldwide, with 70% occurring in developed countries. Mexico is at an intermediate level, being a health problem with a tendency to rise due to the aging of the population. population and higher prevalence of risk factors. Malignant hyperthermia (MH) is an anesthetic-triggered pharmacogenetic disorder that triggers a massive accumulation of calcium in the sarcoplasm, leading to accelerated metabolism and increased skeletal muscle contractile activity. Leading to a hypermetabolic state showing an increase in body temperature, leading to significant sequelae and high mortality. It was a 40-year-old female with no relevant history for anesthetic procedures, being managed with balanced general anesthesia at 60 minutes present data clinicians that they suggested malignant hyperthermia, being managed. With the available means, obtaining a favorable result from the point of view of morbidity and mortality.


REFERENCES

  1. Cáncer, el asesino silencioso de la mujer mexicana. Conversus. Instituto Politécnico Nacional. México. 2006. p. 47.

  2. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition-Summary document. Annals of Oncology. 2008;19:614-622.

  3. Frenk MJ, Ruelas BE, Tapia CR, Castañón RR, de León-May ME, González PE, et al. Compendio de patología mamaria. Secretaría de Salud. México.2002. p. 13-14.

  4. Programa de acción: cáncer de mama. 2007-2012. Secretaría de Salud. México. 2007. p. 11.

  5. Bandschapp O, Girard T. Malignant hyperthermia. Swiss Med Wkly. 2012;142:w13652. doi: 10.4414/smw.2012.13652 Cite this as: Swiss Med Wkly. 2012;142: w13652.

  6. Schiemann AH, Paul N, Parker R, Pollock N, Bulger TF, Stowell KM. Functional characterization of 2 known ryanodine receptor mutations causing malignant hyperthermia. Anesth Analg. 2014;118:375-380. doi: 10.1213/ANE.0b013e3182a273ea.

  7. Visoiu M, Young MC, Wieland K, Brandom BW. Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg. 2014;118:388-396. doi: 10.1213/ANE.0000000000000062.

  8. Brandom BW, Bina S, Wong CA, Wallace T, Visoiu M, Isackson PJ, et al. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States. Anesth Analg. 2013;116:1078-1086. doi: 10.1213/ANE.0b013e31828a71ff.

  9. Glahn KP, Ellis FR, Halsall PJ, Müller CR, Snoeck MM, Urwyler A, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth. 2010;105:417-420. doi: 10.1093/bja/aeq243.

  10. Schuster F, Moegele S, Johannsen S, Roewer N. Malignant hyperthermia in the intensive care setting. Crit Care. 2014;18:411. doi: 10.1186/cc13744.

  11. Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands. Anesth Analg. 2014;118:381-387. doi: 9.1213/ANE.0b013e3182937d8b.

  12. Sumitani M, Uchida K, Yasunaga H, Horiguchi H, Kusakabe Y, Matsuda S, et al. Prevalence of malignant hyperthermia and relationship with anesthetics in Japan: data from the diagnosis procedure combination database. Anesthesiology. 2011;114:84-90. doi: 10.1097/ALN.0b013e318200197d. Erratum in: Anesthesiology. 2011;114:1257.

  13. Cottron N, Larcher C, Sommet A, Fesseau R, Alacoque X, Minville V, et al. The sevoflurane washout profile of seven recent anesthesia workstations for malignant hyperthermia-susceptible adults and infants: a bench test study. Anesth Analg. 2014;119:67-75. doi: 10.1213/ANE.0000000000000208.

  14. Correia AC, Silva PC, da Silva BA. Malignant hyperthermia: clinical and molecular aspects. Rev Bras Anestesiol. 2012;62:820-837. doi: 10.1016/S0034-7094(12)70182-4.

  15. Hopkins PM. Malignant hyperthermia: pharmacology of triggering. Br J Anaesth. 2011;107:48-56. doi: 10.1093/bja/aer132.




2020     |     www.medigraphic.com